Walleye Capital LLC Tcr2 Therapeutics Inc. Transaction History

Walleye Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $488,529 - $958,739	-203,554 Closed	0 $0
Q4 2021 Mar 03, 2022	BUY	$4.58 - $8.34 $441,310 - $803,609	96,356 Added 89.89%	203,554 $948,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $766,039 - $1.67 Million	90,763 Added 552.25%	107,198 $912,000
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $269,698 - $406,108	16,435 New	16,435 $270,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.